---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-071953"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:01:47.537405+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner

## Summary
- Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).
- Key secondary endpoint F-VASI75 also not met (9.8% vs 6.4%, p=0.1468).
- Nominal statistical significance for 3% dose on percent CFB in F-VASI (-43.6% vs -25.6%, p=0.002) and T-VASI (-28.3% vs -16.2%, p=0.044).
- High vehicle effect and dropout rate in active arms (36.6% for 3% vs 10.6% vehicle); company ends trial extension phase.
- Preliminary cash $39.6M as of June 30, 2025; company seeking partner for Repibresib.

## SEC filing metadata
- accession: 0001104659-25-071953
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465925071953/0001104659-25-071953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465925071953/tm2522042d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-071953
- JSON: https://secwatch.observer/filing/0001104659-25-071953.json
- Plain text: https://secwatch.observer/filing/0001104659-25-071953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.